Geron
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Geron and other ETFs, options, and stocks.About GERN
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies.
GERN Key Statistics
Stock Snapshot
With a market cap of 922.42M, Geron(GERN) trades at $1.46. The stock has a price-to-earnings ratio of -11.19.
As of 2026-03-04, Geron(GERN) stock has fluctuated between $1.42 and $1.57. The current price stands at $1.46, placing the stock +2.8% above today's low and -7.0% off the high.
Geron(GERN) shares are trading with a volume of 21.45M, against a daily average of 22.38M.
During the past year, Geron(GERN) stock moved between $1.04 at its lowest and $2.01 at its peak.
During the past year, Geron(GERN) stock moved between $1.04 at its lowest and $2.01 at its peak.
GERN News
Advertisement Recent price performance and business context Geron (GERN) has been moving on mixed recent returns, with a 7.7% decline over the past day and a...
Geron Corporation has reported its full-year 2025 results, with revenue of US$183.88 million versus US$76.99 million a year earlier, and a net loss of US$85.78...
Reports Q4 revenue $48M, consensus $50.43M. “Strategic actions we have taken in the second half of 2025 position Geron (GERN) to drive RYTELO demand growth and...
Analyst ratings
67%
of 6 ratingsMore GERN News
For fiscal year 2026, the Company expects Rytelo net product revenue to be in the range of $220 million to $240 million. Geron (GERN) also expects total operati...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.